Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
-
Published:2016-06
Issue:
Volume:60
Page:190-209
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Hofmann LarsORCID, Forschner Andrea, Loquai Carmen, Goldinger Simone M., Zimmer Lisa, Ugurel Selma, Schmidgen Maria I., Gutzmer Ralf, Utikal Jochen S., Göppner Daniela, Hassel Jessica C.ORCID, Meier Friedegund, Tietze Julia K., Thomas IoannisORCID, Weishaupt CarstenORCID, Leverkus Martin, Wahl Renate, Dietrich Ursula, Garbe Claus, Kirchberger Michael C., Eigentler Thomas, Berking Carola, Gesierich Anja, Krackhardt Angela M., Schadendorf Dirk, Schuler Gerold, Dummer Reinhard, Heinzerling Lucie M.
Subject
Cancer Research,Oncology
Reference50 articles.
1. PD-1 and PD-1 ligands: from discovery to clinical application;Okazaki;Int Immunol [Internet],2007 2. Tumor immunotherapy directed at PD-1;Ribas;N Engl J Med [Internet],2012 3. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med [Internet],2010 4. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma;Robert;N Engl J Med [Internet],2011 5. Pembrolizumab versus ipilimumab in advanced melanoma;Robert;N Engl J Med [Internet],2015
Cited by
566 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|